Journal Browser

► Journal Browser

Clinical Advances in the Diagnosis and Treatment of Thyroid Autoimmune Disorders and Thyroid Cancer

Share This Special Issue

Special Issue Editors

Special Issue Information

Dear Colleagues,

Autoimmune thyroid diseases are very common in the general population, and in recent decades there has also been an increase in the incidence and mortality of thyroid cancer. Furthermore, the widespread use of new oncological therapies, including immunotherapy, has brought out new thyroid side effects that require rapid identification and medical management to minimize the impact on patients already suffering from the neoplastic disease. Several data have also demonstrated that there is an association between autoimmune thyroid diseases, thyroid cancers, and other autoimmune immune diseases, both systemic and organ specific, such as systemic sclerosis, LES, psoriasis, and arthritis. Last but not least, in preliminary studies, a certain impact of the SARS-CoV2 pandemic on the functionality and homeostasis of the immune system, with subsequent autoimmune sequelae, emerged, further expanding the exposed population to these clinical conditions. For these reasons, with this Special Issue, we would like to collect original articles and reviews that aim to expand and update the knowledge regarding the pathophysiology and clinical management of the broad spectrum of autoimmune and thyroid diseases, with a specific focus on their interactions.

Dr. Armando Patrizio
Dr. Poupak Fallahi
Dr. Silvia Martina Ferrari
Prof. Dr. Yehuda Shoenfeld
Prof. Dr. Alessandro Antonelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

thyroid cancer
autoimmune thyroid diseases
thyroid irAE
Graves’ disease
thyroid eye disease
molecular basis of thyroid cancer
advanced thyroid cancer
tyrosine kinase inhibitors
medullary thyroid cancer

Published Papers (1 paper)

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Review

12 pages, 516 KiB

Open AccessReview

Thyroid Autoimmunity and SARS-CoV-2 Infection

by Poupak Fallahi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Armando Patrizio, Eugenia Balestri, Valeria Mazzi, Salvatore Benvenga, Gilda Varricchi, Laura Gragnani, Chiara Botrini, Enke Baldini, Marco Centanni, Clodoveo Ferri, Alessandro Antonelli and Silvia Martina Ferrari

J. Clin. Med. 2023, 12(19), 6365; https://doi.org/10.3390/jcm12196365 - 05 Oct 2023

Cited by 3 | Viewed by 2127

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological culprit of COronaVIrus Disease 19 (COVID-19), can enter the cells via the angiotensin-converting enzyme 2 (ACE2) receptor, which has been found in several tissues including in endocrine organs, such as the ovaries, testes, pancreas, and thyroid. Several thyroid disorders have been associated with SARS-CoV-2 infection [subacute thyroiditis (SAT), thyrotoxicosis, and non-thyroidal illness syndrome (NTIS)] and, in part, they are believed to be secondary to the local virus replication within the gland cells. However, as documented for other viruses, SARS-CoV-2 seems to interfere with several aspects of the immune system, inducing the synthesis of autoantibodies and triggering latent or new onset autoimmune disease (AID), including autoimmune thyroid disease (AITD), such as Hashimoto Thyroiditis (HT) and Graves’ disease (GD). Several mechanisms have been hypothesized to explain this induction of autoimmunity by SARS-CoV-2 infection: the immune system hyper-stimulation, the molecular mimicry between the self-antigens of the host and the virus, neutrophils extracellular traps, and finally, the virus induced transcriptional changes in the immune genes; nonetheless, more evidence is needed especially from large, long-term cohort studies involving COVID-19 patients, to establish or reject this pathogenetic relationship. Full article

(This article belongs to the Special Issue Clinical Advances in the Diagnosis and Treatment of Thyroid Autoimmune Disorders and Thyroid Cancer)

► Show Figures

Journal Menu

Journal Browser

Clinical Advances in the Diagnosis and Treatment of Thyroid Autoimmune Disorders and Thyroid Cancer

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (1 paper)

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI